Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 9/20 | 0.41 |
| ▸ | BRD2 | P25440 | 8/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 8/20 | 0.41 |
| ▸ | QPCT | Q16769 | 9/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900460 | 0.87 | QPCT (0.40) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL22900454 | 0.85 | QPCT (0.41) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL22900221 | 0.83 | QPCT (0.53) | QPCT | |
| SCHEMBL22900430 | 0.78 | QPCT (0.41) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL22900328 | 0.77 | BRD2 (0.44) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL22900398 | 0.77 | BRD4 (0.36) | BRD4BRD3BRD2CREBBPMDM2 | |
| SCHEMBL22900325 | 0.76 | QPCT (0.40) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL22900459 | 0.73 | QPCT (0.40) | BRD4BRD3BRD2CREBBPQPCT | |
| SCHEMBL3814664 | 0.71 | QPCT (0.42) | QPCTMDM2TP53 | |
| SCHEMBL22900181 | 0.71 | QPCT (0.52) | BRD4BRD3BRD2CREBBPQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021009068-A1 | N-SUBSTITUTED-3,4-(FUSED 5-RING)-5-PHENYL-PYRROLIDINE-2-ONE COMPOUNDS AS INHIBITORS OF ISOQC AND/OR QC ENZYME | SCENIC IMMUNOLOGY B.V. (NL) | 2021-01-21 | — | — | WO | disclosed |